[Preoperative administration of new GPIIb/IIIa inhibitors].
The influence of preoperative abciximab treatment on perioperative risks was analyzed. Six groups were formed in consecutive patients (n = 957, 1/1994-3/2000) operated upon for CABG according to the urgency of the intervention and the type of preoperative haemostaseological treatment. Thirty-one patients underwent urgent/emergency CABG with preceding abciximab treatment. After pretreatment with abciximab the surgical results did not differ from patients with other types of preoperative haemostaseological treatment. CABG can be performed with similar results in abciximab pretreated patients as in patients with other types of preoperative haemostaseological treatment.
Vahl
C F
CF
Klinik für Herzchirurgie, Im Neuenheimer Feld 110, 69120 Heidelberg.
Kayhan
N
N
Hagl
S
S
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D016063:Blood Loss, Surgical / Q000503:physiopathology*; D001026:Coronary Artery Bypass; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D019934:International Normalized Ratio; D010314:Partial Thromboplastin Time; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011292:Premedication
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab